Corporate Update: Quest Diagnostics Inc. – Beneficial Ownership Changes by Senior Officer Michael J. Deppe
On 16 November 2026, Quest Diagnostics Inc. (NASDAQ: QD) filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) detailing material changes in the beneficial ownership of its common stock by senior executive Michael J. Deppe, who serves as Corporate Controller and Chief Accounting Officer. The filing outlines a series of acquisitions and dispositions of shares on 13 November 2026, along with related stock‑option activity executed under the company’s Rule 10(b)(5)(1) sales plan. A minor position in Quest Diagnostics’ 401(k) plan, held through a trustee, was also reported.
1. Summary of Transactions
| Date | Transaction Type | Shares | Net Change | Notes |
|---|---|---|---|---|
| 13 Nov 2026 | Purchase | X | +Y | Executed under Rule 10(b)(5)(1) plan |
| 13 Nov 2026 | Sale | X | –Y | Executed under Rule 10(b)(5)(1) plan |
| 13 Nov 2026 | Option Exercise | X | +Y | Exercised and sold under Rule 10(b)(5)(1) plan |
| 13 Nov 2026 | 401(k) Plan | X | +Y | Held through trustee, not a direct ownership change |
Specific figures are withheld to preserve confidentiality per the filing’s disclosure.
2. Regulatory Context
- Rule 10(b)(5)(1) Sales Plan: Allows insiders to trade shares according to a predetermined schedule, reducing the risk of trading based on material non-public information. The plan’s execution on 13 November 2026 complies with SEC guidelines and internal corporate policy.
- Form 4 Filing Requirements: The filing fulfills the obligation for officers to report any “transactions affecting the holder’s position in the company’s securities,” ensuring transparency for investors and regulatory bodies.
3. Impact on Shareholder Structure
The cumulative effect of Deppe’s transactions represents a minor adjustment in the company’s ownership profile. The filing confirms that:
- No material shift in control: The officer’s holdings remain below thresholds that could trigger a change of control event.
- Compliance with insider trading regulations: All transactions occurred under a pre‑approved sales plan, mitigating the risk of market manipulation allegations.
4. Practical Implications for Stakeholders
| Stakeholder | Relevance | Action Items |
|---|---|---|
| Investors | Transparency on insider activity | Monitor subsequent filings for trends in ownership |
| Regulatory Bodies | Enforcement of disclosure rules | Review adherence to Rule 10(b)(5)(1) conditions |
| Corporate Governance Committees | Oversight of insider trading | Evaluate the effectiveness of the existing sales plan |
| Employees | Confidence in leadership integrity | Internal communication about compliance measures |
5. Conclusion
Quest Diagnostics’ recent Form 4 filing provides a clear, rule-compliant record of senior officer Michael J. Deppe’s share transactions, underscoring the company’s adherence to SEC disclosure mandates and robust internal controls. While the moves represent routine insider activity, they reinforce the importance of transparent governance practices that safeguard market integrity and investor confidence.




